Delivery Order SPE2DB22D9207-SPE2DB25FH4ZF
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,782.32 to DMS Pharmaceutical Group Inc. for the supply of Alecensa 150 mg capsules (240 count units). The contract was awarded on August 29, 2025, with an ultimate completion date of September 22, 2025, and carries a firm fixed-price structure with no set-aside designation. The delivery location is Park Ridge, Illinois, where DMS Pharmaceutical Group maintains its headquarters operations. DMS Pharmaceutical Group Inc., a...
- The Defense Logistics Agency awarded a delivery order valued at $12,782.32 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Alecensa 150 mg capsules (240-unit quantity). This firm fixed-price delivery order, issued on September 3, 2025, with an ultimate completion date of September 24, 2025, carries no set-aside designation. The award falls under DMS Pharmaceutical Group's existing single-award Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $12,782.32 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Alecensa 150 mg capsules (240-count units). This firm fixed-price delivery order, issued on August 8, 2025, with an ultimate completion date of August 29, 2025, represents a direct procurement for pharmaceutical products supporting Department of Defense healthcare needs. The contract...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $12,782.32 to DMS Pharmaceutical Group Inc. for the supply of Alecensa 150 mg capsules (240-count units). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform this delivery order at its Park Ridge location with an ultimate completion date of September 10, 2025. This award carries no set-aside designation, allowing the vendor to compete on...
- The Defense Logistics Agency awarded a $25.6K firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 240 units of Alecensa 150 mg capsules. The contract was awarded on September 18, 2025, with an ultimate completion date of October 9, 2025, and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA valued...
- The Defense Logistics Agency awarded a $12.78K delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Alecensa 150 mg capsules (240 count). The contract, issued on August 5, 2025, with an ultimate completion date of August 26, 2025, represents a firm fixed-price delivery order with no set-aside designation. This award is issued under DMS Pharmaceutical Group's existing single-award Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order by the Defense Logistics Agency (DLA) on July 14, 2025, for the supply of Alecensa 150 mg capsules (240-count units) with a ceiling value of $25.6K. This delivery order, which carries no set-aside designation, is scheduled for completion by August 4, 2025, and will be performed at the contractor's facility in Park Ridge, Illinois....
- The Defense Logistics Agency awarded a delivery order valued at $12,782.32 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Alecensa 150 mg capsules (240-count units). This firm fixed-price delivery order, awarded on August 28, 2025, with an ultimate completion date of September 19, 2025, represents a direct fulfillment of pharmaceutical needs within the federal supply chain. The contract carries no...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Alecensa 150 mg capsules (240-count units). This firm fixed-price delivery order, awarded on July 21, 2025, carries a ceiling value of $12,782.32 and is scheduled for ultimate completion by August 11, 2025. The contract was awarded without a set-aside designation, allowing DMS Pharmaceutical Group to compete...
- The U.S. Defense Logistics Agency (DLA), acting through the Medical Supply Chain organization, awarded a delivery order to DMS Pharmaceutical Group Inc. on June 9, 2025, for the supply of Alecensa 150 mg capsules in quantities of 240 units. This firm fixed-price delivery order, valued at $38,346.96, represents a single task issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with DLA under the SPE2DB program, which carries a maximum value of $499,999,999 and extends...
- SPE2DB22D9207Indefinite Delivery Contract
- SPE2DB22D9207-SPE2DB25FH4ZFDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,782.32 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Alecensa 150 mg capsules (240-count units). This firm fixed-price delivery order, issued on April 24, 2025, with an ultimate completion date of May 15, 2025, represents a continuation of the companies' established relationship under the larger pharmaceutical supply framework. The award carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on equal footing with other qualified vendors despite its small business status. This delivery order is issued under DMS Pharmaceutical Group's significant single-award Indefinite Delivery Contract with the DLA valued at $499,999,999 and valid through November 2026. The parent IDC enables the agency to procure a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables to support Department of Defense healthcare facilities worldwide. Alecensa, an oncology treatment medication, aligns with the contractor's demonstrated capability to supply specialized pharmaceutical products directly to military medical installations across the global defense healthcare supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.8k | 4/24/25 |